aidsВИЧ-инфекция и иммуносупрессииHIV Infection and Immunosuppressive Disorders2077-9828Baltic Medical Education Center10.22328/2077-9828-2022-14-3-7-23aids-729Research ArticleАНАЛИТИЧЕСКИЙ ОБЗОРANALYTICAL REVIEWФармакокинетические и фармакодинамические особенности взаимодействия антиретровирусных препаратовPharmacokinetic and pharmacodynamic features of antiretroviral productshttps://orcid.org/0000-0003-0725-5455УсеиноваА. Н.UseinovaA. N.

Усеинова Асие Наримановна — кандидат медицинских наук, доцент кафедры базисной и клинической фармакологии

295051, Республика Крым, г. Симферополь, бул. Ленина, д. 5/7

SPINкод 9031–2079

Asie N. Useinova

Simferopol

mametova.as@mail.ruhttps://orcid.org/0000-0003-4012-2523ЕгороваЕ. А.EgorovaE. A.

Егорова Елена Александровна — кандидат фармацевтических наук, доцент кафедры базисной и клинической фармакологии

295051, Республика Крым, г. Симферополь, бул. Ленина, д. 5/7

SPINкод 6856–7328

Simferopol

egorovapharm@mail.ruhttps://orcid.org/0000-0003-0765-5336МарьяненкоС. П.MaryanenkoS. P.

Марьяненко София Павловна — студентка V курса специальности «Лечебное дело»

295051, Республика Крым, г. Симферополь, бул. Ленина, д. 5/7

Simferopol

sofiya-maryanenko@mail.ruКалиберденкоВ. Б.KaliberdenkoV. B.

Калиберденко Виталий Борисович — кандидат медицинских наук, доцент кафедры внутренней медицины № 2 

295051, Республика Крым, г. Симферополь, бул. Ленина, д. 5/7

Simferopol

kaliberdenkovb@cfuv.ruhttps://orcid.org/0000-0003-1571-9301КоряноваК. Н.KoryanovaK. N.

Корянова Ксения Николаевна — кандидат фармацевтических наук, доцент кафедры фармакологии с курсом клинической фармакологии

357532, Ставропольский край, г. Пятигорск, пр. Калинина, д. 11

Pyatigorsk

kskor-16@mail.ruhttps://orcid.org/0000-0002-3509-8824ГригорянК. Е.GrogoryanK. E.

Григорян Кристина Ерджаниковна — студентка V курса специальности 31.05.03 «Стоматология»

357532, Ставропольский край, г. Пятигорск, пр. Калинина, д. 11

Pyatigorsk

gevorkyan.kristina2505@yandex.ruИнститут «Медицинская академия имени С. И. Георгиевского» ФГАОУ ВО «Крымский федеральный университет имени В. И. Вернадского»РоссияInstitute «Medical Academy named S. I. Georgievsky» Crimean Federal University named V. I. VernadskyRussian FederationПятигорский медико-фармацевтический институтРоссияPyatigorsk Medical and Pharmaceutical InstituteRussian Federation202209112022143723Copyright © Усеинова А.Н., Егорова Е.А., Марьяненко С.П., Калиберденко В.Б., Корянова К.Н., Григорян К.Е., 20222022Усеинова А.Н., Егорова Е.А., Марьяненко С.П., Калиберденко В.Б., Корянова К.Н., Григорян К.Е.Useinova A.N., Egorova E.A., Maryanenko S.P., Kaliberdenko V.B., Koryanova K.N., Grogoryan K.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://hiv.bmoc-spb.ru/jour/article/view/729Введение

Введение. С момента появления вируса иммунодефицита (ВИЧ) и синдрома приобретенного иммунодефицита (СПИД) в начале 1980-х годов человечество начало понимать элементарные процессы, лежащие в основе биологии ВИЧ, что дало возможность разработки безопасных и эффективных методов лечения. В настоящий момент терапия ВИЧ включает комбинированные схемы лечения, что обусловливает возможность взаимодействия лекарственных средств в комбинации.

Цель

Цель. Изучение особенностей фармакокинетики и фармакодинамики, а также межлекарственного взаимодействия отдельных групп препаратов, влияющих на вирус иммунодецифита человека.

Материалы и методы

Материалы и методы. Аналитический обзор основан на анализе источников литературы научных баз данных (PubMed, Cochrane Library, Сyberleninka), содержащих информацию об особенностях фармакокинетических и фармакодинамических взаимодействий антиретровирусных препаратов (АРВП) при их применении у ВИЧ-инфицированных пациентов за период 1995–2022 гг.

Результаты и их обсуждение. Настоящий обзор позволил обобщить результаты исследований, посвященных вопросам комбинированного применения антиретровирусных препаратов у ВИЧ-инфицированных пациентов, а также выявить варианты нерациональных комбинаций АРВП, обусловленных повышением риска развития токсичности при их одновременном применении.

Заключение

Заключение. Изучение характерных особенностей каждого из лекарственного препарата, применяющегося в терапии ВИЧ-инфекции, позволяет осуществлять выбор оптимальной схемы фармакотерапии с учетом индивидуальных особенностей пациента, а также прогнозировать и предотвращать риски развития нежелательных реакций в будущем.

Introduction

Introduction. Since the appearance of the immune deficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) at the beginning of 1980s, humanity started to understand elementary processes, underlying biology of HIV that enabled to develop safe and efficient treatment methods. Currently HIV therapy includes combined treatment regimen that allows combined drug interaction.

Objective

Objective. To study the features of pharmacokinetics and pharmacodynamics, and also drug interaction of specific product groups, affecting human immunodeficiency virus.

Materials and methods

Materials and methods. Analytical review is based on analysis of literary sources of scientific database (PubMed, Cochrane Library, Сyberleninka) that contains information about peculiarities of pharmacokinetic and pharmacodynamic antiretroviral products’ interaction (ARVP) when used by HIV-infected patients for the period 1995–2022. 

Results and discussion

Results and discussion. The current study enabled to summarize the research results, devoted to the issue of combined ARVP use by HIV-infected patients, and also to identify variants of irrational ARVP combination, caused by increased risk of toxicity with their simultaneous application.

Conclusion

Conclusion. Studying the characteristics of each medical product, used in HIV infection therapy, allows to choose optimal pharmacotherapy regimens, taking into account individual patient characteristics, and also to predict and prevent the risk of adverse reactions in the future.

антиретровирусная терапияВИЧ-инфекциябезопасность фармакотерапиинежелательные реакциивзаимодействие препаратовantiretroviral therapyHIV-infectionpharmacotherapy safetyadverse reactionsdrug interactionReferencesTang M.W., Shafer R.W. HIV-1 antiretroviral resistance: scientific principles and clinical applications // Drugs. 2012. Vol. 72, No. 9. e1–25. DOI: 10.2165/11633630-000000000-00000.Tang M.W., Shafer R.W. HIV-1 antiretroviral resistance: scientific principles and clinical applications // Drugs. 2012. Vol. 72, No. 9. e1–25. DOI: 10.2165/11633630-000000000-00000.Вавилова В.А., Шекунова Е.В., Джайн (Корсакова) Е.А., Балабаньян В.Ю., Озеров А.А., Макарова М.Н., Макаров В.Г. Экспериментальное изучение токсических свойств препарата VMU-2012-05 — оригинального ненуклеозидного ингибитора обратной транскриптазы ВИЧ-1 // Фармация и фармакология. 2021. Т. 9, № 3. С. 205–221. DOI: 10.19163/2307-9266-2021-9-3-205-221.Vavilova V.A., Shekunova E.V., Jain (Korsakova) E.A., Balabanyan V.Yu., Ozerov A.A., Makarova M.N., Makarov V.G. Experimental study of toxic properties of VMU-2012-05 drug — original nonnucleeside inhibitor of HIV-1 reverse transcriptase. Pharmacy & Pharmacology, 2021, Vol. 9, No. 3, рр. 205–221 (In Russ.). DOI: 10.19163/2307-9266-2021-9-3-205-221.Saag M.S., Benson C.A., Gandhi R.T., Hoy J.F., Landovitz R.J., Mugavero M.J., Sax P.E., Smith D.M., Thompson M.A., Buchbinder S.P., Del Rio C., Eron J.J.Jr., Fätkenheuer G., Günthard H.F., Molina J.M., Jacobsen D.M., Volberding P.A. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel // JAMA. 2018. Vol. 320, No. 4. Р. 379–396. DOI: 10.1001/jama.2018.8431.Saag M.S., Benson C.A., Gandhi R.T., Hoy J.F., Landovitz R.J., Mugavero M.J., Sax P.E., Smith D.M., Thompson M.A., Buchbinder S.P., Del Rio C., Eron J.J.Jr., Fätkenheuer G., Günthard H.F., Molina J.M., Jacobsen D.M., Volberding P.A. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel // JAMA. 2018. Vol. 320, No. 4. Р. 379–396. DOI: 10.1001/jama.2018.8431.Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Канестри В.Г., Шахгильдян В.И., Козырина Н.В., Буравцова В.В., Нарсия Р.С., Покровская А.В., Ефремова О.С., Коннов В.В., Куимова А.Г., Попова А.А., Хохлова О.Н. Национальные рекомендации по диспансерному наблюдению и лечению ВИЧ-инфекцией. Клинический протокол // Эпидемиология и инфекционные болезни. Актуальные вопросы. 2016. № 6 (приложение). 120 с.Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Ermak T.N., Kanestri V.G., Shahgildyan V.I., Kozyrina N.V., Buravtsova V.V., Narsia R.S., Pokrovskaya A.V., Efremova O.S., Konnov V.V., Kuimova A.G., Popov A.A. Khokhlova H.E. National Guidelines for the Dispensary Surveillance and Treatment of HIV-infection. Clinical Protocol. Epidemiology and infectious diseases. Topical issues, 2016, Vol. 6 (Appendix), 120 р. (In Russ.).Lukhwareni A., Gededzha M.P., Amponsah-Dacosta E., Blackard J.T., Burnett R.J., Selabe S.G., Kyaw T., Mphahlele M.J. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans // Viruses. 2020. Vol. 12, No. 6. Р. 634. DOI: 10.3390/v12060634.Lukhwareni A., Gededzha M.P., Amponsah-Dacosta E., Blackard J.T., Burnett R.J., Selabe S.G., Kyaw T., Mphahlele M.J. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans // Viruses. 2020. Vol. 12, No. 6. Р. 634. DOI: 10.3390/v12060634.Quercia R., Perno C.F., Koteff J., Moore K., McCoig C., St Clair M., Kuritzkes D. Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection // J. Acquir. Immune Defic Syndr. 2018. Vol. 78, No. 2. Р. 125–135. DOI: 10.1097/QAI.0000000000001660. PMID: 29474268; PMCID: PMC5959256.Quercia R., Perno C.F., Koteff J., Moore K., McCoig C., St Clair M., Kuritzkes D. Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection // J. Acquir. Immune Defic Syndr. 2018. Vol. 78, No. 2. Р. 125–135. DOI: 10.1097/QAI.0000000000001660. PMID: 29474268; PMCID: PMC5959256.Dionne B. Key Principles of Antiretroviral Pharmacology // Infect. Dis. Clin. North Am. 2019. Vol. 33, No. 3. Р. 787–805. DOI: 10.1016/j.idc.2019.05.006.Dionne B. Key Principles of Antiretroviral Pharmacology // Infect. Dis. Clin. North Am. 2019. Vol. 33, No. 3. Р. 787–805. DOI: 10.1016/j.idc.2019.05.006.Ross L.L., Rouse E., Gerondelis P., DeJesus E., Cohen C., Horton J., Ha B., Lanier E.R., Elion R; COL40263 study. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir // Antimicrob Chemother. 2010. Vol. 65, No. 2. Р. 307–315. DOI: 10.1093/jac/dkp419.Ross L.L., Rouse E., Gerondelis P., DeJesus E., Cohen C., Horton J., Ha B., Lanier E.R., Elion R; COL40263 study. Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir // Antimicrob Chemother. 2010. Vol. 65, No. 2. Р. 307–315. DOI: 10.1093/jac/dkp419.Lee J.S., Paintsil E., Gopalakrishnan V., Ghebremichael M. A comparison of machine learning techniques for classification of HIV patients with antiretroviral therapy-induced mitochondrial toxicity from those without mitochondrial toxicity // BMC Med. Res. Methodol. 2019. Vol. 19, No. 1. Р. 216. DOI: 10.1186/s12874-019-0848-z.Lee J.S., Paintsil E., Gopalakrishnan V., Ghebremichael M. A comparison of machine learning techniques for classification of HIV patients with antiretroviral therapy-induced mitochondrial toxicity from those without mitochondrial toxicity // BMC Med. Res. Methodol. 2019. Vol. 19, No. 1. Р. 216. DOI: 10.1186/s12874-019-0848-z.Young C.K.J., Wheeler J.H., Rahman M.M., Young M.J. The antiretroviral 2’,3’-dideoxycytidine causes mitochondrial dysfunction in proliferating and differentiated HepaRG human cell cultures // Biol. Chem. 2021. Vol. 296. Р. 100206. DOI: 10.1074/jbc.RA120.014885.Young C.K.J., Wheeler J.H., Rahman M.M., Young M.J. The antiretroviral 2’,3’-dideoxycytidine causes mitochondrial dysfunction in proliferating and differentiated HepaRG human cell cultures // Biol. Chem. 2021. Vol. 296. Р. 100206. DOI: 10.1074/jbc.RA120.014885.Van Vonderen M.G., Lips P., van Agtmael M.A., Hassink E.A., Brinkman K., Geerlings S.E., Sutinen J., Ristola M., Danner S.A., Reiss P. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir // AIDS. 2009. Vol. 23, No. 11. Р. 1367–1376. DOI: 10.1097/QAD.0b013e32832c4947.Van Vonderen M.G., Lips P., van Agtmael M.A., Hassink E.A., Brinkman K., Geerlings S.E., Sutinen J., Ristola M., Danner S.A., Reiss P. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir // AIDS. 2009. Vol. 23, No. 11. Р. 1367–1376. DOI: 10.1097/QAD.0b013e32832c4947.Agarwal K., Brunetto M., Seto W.K., Lim Y.S., Fung S., Marcellin P., Ahn S.H., Izumi N., Chuang W.L., Bae H., Sharma M., Janssen H.L.A., Pan C.Q., Çelen M.K., Furusyo N., Shalimar D., Yoon K.T., Trinh H., Flaherty J.F., Gaggar A., Lau A.H., Cathcart A.L., Lin L., Bhardwaj N., Suri V., Mani Subramanian G., Gane E.J., Buti M., Chan H.L.Y.; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection // Hepatol. 2018. Vol. 68, No. 4. Р. 672–681. DOI: 10.1016/j.jhep.2017.11.039.Agarwal K., Brunetto M., Seto W.K., Lim Y.S., Fung S., Marcellin P., Ahn S.H., Izumi N., Chuang W.L., Bae H., Sharma M., Janssen H.L.A., Pan C.Q., Çelen M.K., Furusyo N., Shalimar D., Yoon K.T., Trinh H., Flaherty J.F., Gaggar A., Lau A.H., Cathcart A.L., Lin L., Bhardwaj N., Suri V., Mani Subramanian G., Gane E.J., Buti M., Chan H.L.Y.; GS-US-320-0110; GS-US-320-0108 Investigators. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection // Hepatol. 2018. Vol. 68, No. 4. Р. 672–681. DOI: 10.1016/j.jhep.2017.11.039.Lee W.A., Cheng A.K. Tenofovir alafenamide fumarate // Antivir Ther. 2022. Vol. 27, No. 2. 13596535211067600. DOI: 10.1177/13596535211067600.Lee W.A., Cheng A.K. Tenofovir alafenamide fumarate // Antivir Ther. 2022. Vol. 27, No. 2. 13596535211067600. DOI: 10.1177/13596535211067600.Pribut N., D’Erasmo M., Dasari M., Giesler K.E., Iskandar S., Sharma S.K., Bartsch P.W., Raghuram A., Bushnev A., Hwang S.S., Burton S.L., Derdeyn C.A., Basson A.E., Liotta D.C., Miller E.J. w-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties // Med. Chem. 2021. Vol. 64, No. 17. Р. 12917–12937. DOI: 10.1021/acs.jmedchem.1c01083.Pribut N., D’Erasmo M., Dasari M., Giesler K.E., Iskandar S., Sharma S.K., Bartsch P.W., Raghuram A., Bushnev A., Hwang S.S., Burton S.L., Derdeyn C.A., Basson A.E., Liotta D.C., Miller E.J. w-Functionalized Lipid Prodrugs of HIV NtRTI Tenofovir with Enhanced Pharmacokinetic Properties // Med. Chem. 2021. Vol. 64, No. 17. Р. 12917–12937. DOI: 10.1021/acs.jmedchem.1c01083.Drak D., Barratt H., Templeton D.J., O’Connor C.C., Gracey D.M. Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service // PLoS One. 2019. Vol. 14, No. 1. e0210106. DOI: 10.1371/journal.pone.0210106. PMID: 30653509; PMCID: PMC6336260.Drak D., Barratt H., Templeton D.J., O’Connor C.C., Gracey D.M. Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service // PLoS One. 2019. Vol. 14, No. 1. e0210106. DOI: 10.1371/journal.pone.0210106. PMID: 30653509; PMCID: PMC6336260.Orkin C., Molina J.M., Negredo E., Arribas J.R., Gathe J., Eron J.J., Van Landuyt E., Lathouwers E., Hufkens V., Petrovic R., Vanveggel S., Opsomer M.; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial // Lancet HIV. 2018. Vol. 5, No. 1. e23-e34. DOI: 10.1016/S23523018(17)30179-0. PMID: 28993180.Orkin C., Molina J.M., Negredo E., Arribas J.R., Gathe J., Eron J.J., Van Landuyt E., Lathouwers E., Hufkens V., Petrovic R., Vanveggel S., Opsomer M.; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial // Lancet HIV. 2018. Vol. 5, No. 1. e23-e34. DOI: 10.1016/S23523018(17)30179-0. PMID: 28993180.Kalemeera F., Godman B., Stergachis A., Rennie T. Tenofovir disoproxil fumarate associated nephrotoxicity: a retrospective cohort study at two referral hospitals in Namibia // Pharmacoepidemiol Drug Saf. 2021. Vol. 30, No. 2. Р. 189–200. DOI: 10.1002/pds.5125.Kalemeera F., Godman B., Stergachis A., Rennie T. Tenofovir disoproxil fumarate associated nephrotoxicity: a retrospective cohort study at two referral hospitals in Namibia // Pharmacoepidemiol Drug Saf. 2021. Vol. 30, No. 2. Р. 189–200. DOI: 10.1002/pds.5125.Al-Majed A.A., Bakheit A.H.H., Al-Qahtani B.M., Al-Kahtani H.M., Abdelhameed A.S. Emtricitabine // Profiles Drug Subst. Excip. Relat. Methodol. 2020. Vol. 45. Р. 55–91. DOI: 10.1016/bs.podrm.2019.10.003.Al-Majed A.A., Bakheit A.H.H., Al-Qahtani B.M., Al-Kahtani H.M., Abdelhameed A.S. Emtricitabine // Profiles Drug Subst. Excip. Relat. Methodol. 2020. Vol. 45. Р. 55–91. DOI: 10.1016/bs.podrm.2019.10.003.Atta M.G., De Seigneux S., Lucas G.M. Clinical Pharmacology in HIV Therapy // Clin J Am Soc Nephrol. 2019. Vol. 14, No. 3. Р. 435–444. DOI: 10.2215/CJN.02240218.Atta M.G., De Seigneux S., Lucas G.M. Clinical Pharmacology in HIV Therapy // Clin J Am Soc Nephrol. 2019. Vol. 14, No. 3. Р. 435–444. DOI: 10.2215/CJN.02240218.Siddiqui G.F., Siddiqui S.A., Verma P., Jaiswal R., Adhaulia A. Pre- and post-sexual exposure prophylaxis of HIV: An update // Indian. J. Sex. Transm. Dis. AIDS. 2019. Vol. 40, No. 2. Р. 184–185. DOI: 10.4103/ijstd.IJSTD_75_17.Siddiqui G.F., Siddiqui S.A., Verma P., Jaiswal R., Adhaulia A. Pre- and post-sexual exposure prophylaxis of HIV: An update // Indian. J. Sex. Transm. Dis. AIDS. 2019. Vol. 40, No. 2. Р. 184–185. DOI: 10.4103/ijstd.IJSTD_75_17.Belyhun Y., Liebert U.G., Maier M. Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia // PLoS One. 2018. Vol. 13, No. 2. e0191970. DOI: 10.1371/journal.pone.0191970.Belyhun Y., Liebert U.G., Maier M. Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia // PLoS One. 2018. Vol. 13, No. 2. e0191970. DOI: 10.1371/journal.pone.0191970.Schinazi R.F., Lloyd R.M. Jr., Nguyen M.H., Cannon D.L., McMillan A., Ilksoy N., Chu C.K., Liotta D.C., Bazmi H.Z., Mellors J.W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides // Antimicrob Agents Chemother. 1993. Vol. 37, No. 4. Р. 875–881. DOI: 10.1128/AAC.37.4.875.Schinazi R.F., Lloyd R.M. Jr., Nguyen M.H., Cannon D.L., McMillan A., Ilksoy N., Chu C.K., Liotta D.C., Bazmi H.Z., Mellors J.W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides // Antimicrob Agents Chemother. 1993. Vol. 37, No. 4. Р. 875–881. DOI: 10.1128/AAC.37.4.875.Ambrosioni J., Petit E., Liegeon G., Laguno M., Miró J.M. Primary HIV-1 infection in users of pre-exposure prophylaxis // Lancet HIV. 2021. Vol. 8, No. 3. e166-e174. DOI: 10.1016/S2352-3018(20)30271-X.Ambrosioni J., Petit E., Liegeon G., Laguno M., Miró J.M. Primary HIV-1 infection in users of pre-exposure prophylaxis // Lancet HIV. 2021. Vol. 8, No. 3. e166-e174. DOI: 10.1016/S2352-3018(20)30271-X.Матвеев А.В., Крашенинников А.Е., Егорова Е.А., Коняева Е.И. Анализ извещений о нежелательных реакциях лекарственных препаратов, применяемых для лечения ВИЧ, зарегистрированных в Республике Крым за период 2011–2016 гг. // Фармация и фармакология. 2018. Т. 6, № 6. С. 568–583. DOI: 10.19163/2307-9266-2018-6-6-568-583.Matveev A.V., Krasheninnikov A.Е., Egorova E.A., Konyaeva E.I. Analysis of adverse drug reaction report forms on the medicines, used for aids treatment (registered in the republic of crimea in the period from 2011 to 2016). Pharmacy & Pharmacology, 2018, Vol. 6, No. 6, рр. 568–583 (In Russ.). DOI: 10.19163/2307-9266-2018-6-6-568-583.Brouillette M.J., Fellows L.K., Mayo N.E. Efavirenz and cognition that matters // AIDS. 2020. Vol. 34, No.7. Р. 1105–1106. DOI: 10.1097/QAD.0000000000002545.Brouillette M.J., Fellows L.K., Mayo N.E. Efavirenz and cognition that matters // AIDS. 2020. Vol. 34, No.7. Р. 1105–1106. DOI: 10.1097/QAD.0000000000002545.Ota R., Ishii H., Tsuda M., Higuchi Y., Yamashita F. A model-based comparative meta-analysis of the efficacy of dolutegravir-based and efavirenz-based regimens in HIV-infected patients // Infect Chemother. 2019. Vol. 25, No. 9. Р. 687–694. DOI: 10.1016/j.jiac.2019.03.015.Ota R., Ishii H., Tsuda M., Higuchi Y., Yamashita F. A model-based comparative meta-analysis of the efficacy of dolutegravir-based and efavirenz-based regimens in HIV-infected patients // Infect Chemother. 2019. Vol. 25, No. 9. Р. 687–694. DOI: 10.1016/j.jiac.2019.03.015.Nelson M., Winston A., Hill A., Mngqibisa R., Bassa A., Orkin C., Rassool M., Rodgers A., Teal V., Kumar S., Teppler H. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine // AIDS. 2021. Vol. 35, No. 5. Р. 759–767. DOI: 10.1097/QAD.0000000000002804.Nelson M., Winston A., Hill A., Mngqibisa R., Bassa A., Orkin C., Rassool M., Rodgers A., Teal V., Kumar S., Teppler H. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine // AIDS. 2021. Vol. 35, No. 5. Р. 759–767. DOI: 10.1097/QAD.0000000000002804.Tseng C.W., Dudley R.A., Chen R., Walensky R.P. Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis // JAMA Netw Open. 2020. Vol. 3, No. 4. e202739. DOI: 10.1001/jamanetworkopen.2020.2739.Tseng C.W., Dudley R.A., Chen R., Walensky R.P. Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis // JAMA Netw Open. 2020. Vol. 3, No. 4. e202739. DOI: 10.1001/jamanetworkopen.2020.2739.Decloedt E.H., Sinxadi P.Z., van Zyl G.U., Wiesner L., Khoo S., Joska J.A., Haas D.W., Maartens G. Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites // Antimicrob. Chemother. 2019. Vol. 74, No. 3. Р. 699–709. DOI: 10.1093/jac/dky481.Decloedt E.H., Sinxadi P.Z., van Zyl G.U., Wiesner L., Khoo S., Joska J.A., Haas D.W., Maartens G. Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites // Antimicrob. Chemother. 2019. Vol. 74, No. 3. Р. 699–709. DOI: 10.1093/jac/dky481.Kappelhoff B.S., Crommentuyn K.M., de Maat M.M., Mulder J.W., Huitema A.D., Beijnen J.H. Practical guidelines to interpret plasma concentrations of antiretroviral drugs // Clin. Pharmacokinet. 2004. Vol. 43, No. 13. Р. 845–853. DOI: 10.2165/00003088-200443130-00002. PMID: 15509183.Kappelhoff B.S., Crommentuyn K.M., de Maat M.M., Mulder J.W., Huitema A.D., Beijnen J.H. Practical guidelines to interpret plasma concentrations of antiretroviral drugs // Clin. Pharmacokinet. 2004. Vol. 43, No. 13. Р. 845–853. DOI: 10.2165/00003088-200443130-00002. PMID: 15509183.Francis J., Mngqibisa R., McIlleron H., Kendall M.A., Wu X., Dooley K.E., Firnhaber C., Godfrey C., Cohn S.E., Denti P., A5093, A5283, A5338 study teams. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment // Clin. Pharmacol. Ther. 2021. Vol. 110, No. 4. Р. 1057–1065. DOI: 10.1002/cpt.2324.Francis J., Mngqibisa R., McIlleron H., Kendall M.A., Wu X., Dooley K.E., Firnhaber C., Godfrey C., Cohn S.E., Denti P., A5093, A5283, A5338 study teams. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment // Clin. Pharmacol. Ther. 2021. Vol. 110, No. 4. Р. 1057–1065. DOI: 10.1002/cpt.2324.Sumari-de Boer M., Schellekens A., Duinmaijer A., Lalashowi J.M., Swai H.J., de Mast Q., van der Ven A., Kinabo G. Efavirenz is related to neu-ropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania // Trop. Med. Int. Health. 2018. Vol. 23, No. 2. Р. 164–172. DOI: 10.1111/tmi.13021.Sumari-de Boer M., Schellekens A., Duinmaijer A., Lalashowi J.M., Swai H.J., de Mast Q., van der Ven A., Kinabo G. Efavirenz is related to neu-ropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania // Trop. Med. Int. Health. 2018. Vol. 23, No. 2. Р. 164–172. DOI: 10.1111/tmi.13021.Cross H.M., Chetty S., Asukile M.T., Hussey H.S., Lee Pan E.B., Tucker L.M. A proposed management algorithm for late-onset efavirenz neu-rotoxicity // S. Afr. Med. J. 2018. Vol. 108, No. 4. Р. 271–274. DOI: 10.7196/SAMJ.2017.v108i4.12914.Cross H.M., Chetty S., Asukile M.T., Hussey H.S., Lee Pan E.B., Tucker L.M. A proposed management algorithm for late-onset efavirenz neu-rotoxicity // S. Afr. Med. J. 2018. Vol. 108, No. 4. Р. 271–274. DOI: 10.7196/SAMJ.2017.v108i4.12914.Neary M., Chappell C.A., Scarsi K.K., Nakalema S., Matovu J., Achilles S.L., Chen B.A., Siccardi M., Owen A., Lamorde M. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART // J. Antimicrob. Chemother. 2019. Vol. 74, No. 10. Р. 3003–3010. DOI: 10.1093/jac/dkz298.Neary M., Chappell C.A., Scarsi K.K., Nakalema S., Matovu J., Achilles S.L., Chen B.A., Siccardi M., Owen A., Lamorde M. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART // J. Antimicrob. Chemother. 2019. Vol. 74, No. 10. Р. 3003–3010. DOI: 10.1093/jac/dkz298.Lewis W., Dalakas M.C. Mitochondrial toxicity of antiviral drugs // Nat. Med. 1995. Vol. 1, No. 5. Р. 417–22. DOI: 10.1038/nm0595-417.Lewis W., Dalakas M.C. Mitochondrial toxicity of antiviral drugs // Nat. Med. 1995. Vol. 1, No. 5. Р. 417–22. DOI: 10.1038/nm0595-417.Courlet P., Guidi M., Alves Saldanha S., Stader F., Traytel A., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A., Csajka C. and the Swiss HIV Cohort Study. Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV // Clin. Pharmacokinet. 2021. Vol. 60, No. 3. Р. 379–390. doi: 10.1007/s40262-020-00946-3.Courlet P., Guidi M., Alves Saldanha S., Stader F., Traytel A., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A., Csajka C. and the Swiss HIV Cohort Study. Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV // Clin. Pharmacokinet. 2021. Vol. 60, No. 3. Р. 379–390. doi: 10.1007/s40262-020-00946-3.Bale M.J., Kearney M.F. Review: HIV-1 phylogeny during suppressive antiretroviral therapy // Curr. Opin. HIV AIDS. 2019. Vol. 14, No. 3. Р. 188–193. DOI: 10.1097/COH.0000000000000535.Bale M.J., Kearney M.F. Review: HIV-1 phylogeny during suppressive antiretroviral therapy // Curr. Opin. HIV AIDS. 2019. Vol. 14, No. 3. Р. 188–193. DOI: 10.1097/COH.0000000000000535.Cipriano M., Pinheiro P.F., Sequeira C.O., Rodrigues J.S., Oliveira N.G., Antunes A.M.M., Castro M., Marques M.M., Pereira S.A., Miranda J.P. Nevirapine Biotransformation Insights: An Integrated In Vitro Approach Unveils the Biocompetence and Glutathiolomic Profile of a Human Hepatocyte-Like Cell 3D Model // Int. J. Mol. Sci. 2020. Vol. 21, No. 11. Р. 3998. DOI: 10.3390/ijms21113998.Cipriano M., Pinheiro P.F., Sequeira C.O., Rodrigues J.S., Oliveira N.G., Antunes A.M.M., Castro M., Marques M.M., Pereira S.A., Miranda J.P. Nevirapine Biotransformation Insights: An Integrated In Vitro Approach Unveils the Biocompetence and Glutathiolomic Profile of a Human Hepatocyte-Like Cell 3D Model // Int. J. Mol. Sci. 2020. Vol. 21, No. 11. Р. 3998. DOI: 10.3390/ijms21113998.Van der Laan L.E., Garcia-Prats A.J., Schaaf H.S., Winckler J.L., Draper H., Norman J., Wiesner L., McIlleron H., Denti P., Hesseling A.C. Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis // Front. Pharmacol. 2021. Vol. 12. 722204. DOI: 10.3389/fphar.2021.722204.Van der Laan L.E., Garcia-Prats A.J., Schaaf H.S., Winckler J.L., Draper H., Norman J., Wiesner L., McIlleron H., Denti P., Hesseling A.C. Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis // Front. Pharmacol. 2021. Vol. 12. 722204. DOI: 10.3389/fphar.2021.722204.Kurita T., Kitaichi T., Nagao T., Miura T., Kitazono Y. Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan // Pharmacoepidemiol. Drug Saf. 2014. Vol. 23, No. 4. Р. 361–371. DOI: 10.1002/pds.3589.Kurita T., Kitaichi T., Nagao T., Miura T., Kitazono Y. Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan // Pharmacoepidemiol. Drug Saf. 2014. Vol. 23, No. 4. Р. 361–371. DOI: 10.1002/pds.3589.Fodor J., Riley B.T., Kass I., Buckle A.M., Borg N.A. The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome // Sci. Rep. 2019. Vol. 9, No. 1. Р. 10523. DOI: 10.1038/s41598-019-47001-1.Fodor J., Riley B.T., Kass I., Buckle A.M., Borg N.A. The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome // Sci. Rep. 2019. Vol. 9, No. 1. Р. 10523. DOI: 10.1038/s41598-019-47001-1.Harrigan P.R., Stone C., Griffin P., Nájera I., Bloor S., Kemp S., Tisdale M., Larder B. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group // Infect. Dis. 2000. Vol. 181, No. 3. Р. 912–920. DOI: 10.1086/315317.Harrigan P.R., Stone C., Griffin P., Nájera I., Bloor S., Kemp S., Tisdale M., Larder B. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group // Infect. Dis. 2000. Vol. 181, No. 3. Р. 912–920. DOI: 10.1086/315317.Peese K.M., Allard C.W., Connolly T., Johnson B.L., Li C., Patel M., Sorensen M.E., Walker M.A., Meanwell N.A., McAuliffe B., Minassian B., Krystal M., Parker D.D., Lewis H.A., Kish K., Zhang P., Nolte R.T., Simmermacher J., Jenkins S., Cianci C., Naidu B.N. 5,6,7,8-Tetrahydro1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors // Med. Chem. 2019. Vol. 62, No. 3. Р. 1348–1361. DOI: 10.1021/acs.jmedchem.8b01473.Peese K.M., Allard C.W., Connolly T., Johnson B.L., Li C., Patel M., Sorensen M.E., Walker M.A., Meanwell N.A., McAuliffe B., Minassian B., Krystal M., Parker D.D., Lewis H.A., Kish K., Zhang P., Nolte R.T., Simmermacher J., Jenkins S., Cianci C., Naidu B.N. 5,6,7,8-Tetrahydro1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors // Med. Chem. 2019. Vol. 62, No. 3. Р. 1348–1361. DOI: 10.1021/acs.jmedchem.8b01473.NAMSAL ANRS 12313 Study Group, Kouanfack C., Mpoudi-Etame M…, Omgba Bassega P., Eymard-Duvernay S., Leroy S., Boyer S., Peeters M., Calmy A., Delaporte E. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1 // N. Engl. J. Med. 2019. Vol. 381, No. 9. Р. 816–826. DOI: 10.1056/NEJMoa1904340NAMSAL ANRS 12313 Study Group, Kouanfack C., Mpoudi-Etame M…, Omgba Bassega P., Eymard-Duvernay S., Leroy S., Boyer S., Peeters M., Calmy A., Delaporte E. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1 // N. Engl. J. Med. 2019. Vol. 381, No. 9. Р. 816–826. DOI: 10.1056/NEJMoa1904340Kawuma A.N., Walimbwa S.I., Pillai G.C., Khoo S., Lamorde M., Wasmann R.E., Denti P. Dolutegravir pharmacokinetics during co-administra-tion with either artemether/lumefantrine or artesunate/amodiaquine // Antimicrob Chemother. 2021. Vol. 76, No. 5. Р. 1269–1272. DOI: 10.1093/jac/dkab022.Kawuma A.N., Walimbwa S.I., Pillai G.C., Khoo S., Lamorde M., Wasmann R.E., Denti P. Dolutegravir pharmacokinetics during co-administra-tion with either artemether/lumefantrine or artesunate/amodiaquine // Antimicrob Chemother. 2021. Vol. 76, No. 5. Р. 1269–1272. DOI: 10.1093/jac/dkab022.Oliveira M., Ibanescu R.I., Anstett K., Mésplède T., Routy J.P., Robbins M.A., Brenner B.G.; Montreal Primary HIV (PHI) Cohort Study Group. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir // Retrovirology. 2018. Vol. 15, No. 1. Р. 56. DOI: 10.1186/s12977-018-0440-3.Oliveira M., Ibanescu R.I., Anstett K., Mésplède T., Routy J.P., Robbins M.A., Brenner B.G.; Montreal Primary HIV (PHI) Cohort Study Group. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir // Retrovirology. 2018. Vol. 15, No. 1. Р. 56. DOI: 10.1186/s12977-018-0440-3.Brenner B.G., Wainberg M.A. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance // Virus Res. 2017. Vol. 239. Р. 1–9. DOI: 10.1016/j.virusres.2016.07.006.Brenner B.G., Wainberg M.A. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance // Virus Res. 2017. Vol. 239. Р. 1–9. DOI: 10.1016/j.virusres.2016.07.006.Kouamou V., Inzaule S., Manasa J. Dolutegravir drug-resistance monitoring in Africa // Lancet HIV. 2021. Vol. 8(11. e664–e666. DOI: 10.1016/S2352-3018(21)00268-X.Kouamou V., Inzaule S., Manasa J. Dolutegravir drug-resistance monitoring in Africa // Lancet HIV. 2021. Vol. 8(11. e664–e666. DOI: 10.1016/S2352-3018(21)00268-X.Van Wyk J., Ajana F., Bisshop F., De Wit S., Osiyemi O., Portilla Sogorb J., Routy J.P., Wyen C., Ait-Khaled M., Nascimento M.C., Pappa K.A., Wang R., Wright J., Tenorio A.R., Wynne B., Aboud M., Gartland M.J., Smith K.Y. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study // Clin. Infect. Dis. 2020. Vol. 71, No. 8. Р. 1920–1929. DOI: 10.1093/cid/ciz1243.Van Wyk J., Ajana F., Bisshop F., De Wit S., Osiyemi O., Portilla Sogorb J., Routy J.P., Wyen C., Ait-Khaled M., Nascimento M.C., Pappa K.A., Wang R., Wright J., Tenorio A.R., Wynne B., Aboud M., Gartland M.J., Smith K.Y. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study // Clin. Infect. Dis. 2020. Vol. 71, No. 8. Р. 1920–1929. DOI: 10.1093/cid/ciz1243.Demarest J., Underwood M., St Clair M., Dorey D., Brown D., Zolopa A. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance // AIDS Res. Hum. Retroviruses. 2018. Vol. 34, No. 4. Р. 343–346. DOI: 10.1089/AID.2017.0184.Demarest J., Underwood M., St Clair M., Dorey D., Brown D., Zolopa A. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance // AIDS Res. Hum. Retroviruses. 2018. Vol. 34, No. 4. Р. 343–346. DOI: 10.1089/AID.2017.0184.Castagna A., Ferrara M., Galli L., Comi L., Sterrantino G., Cenderello G., Zaccarelli M., Focà E., Roncadori A., Lazzarin A.; PRESTIGIO Study Group. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus // Antimicrob. Chemother. 2018. Vol. 73, No. 1. Р. 177–182. DOI: 10.1093/jac/dkx371.Castagna A., Ferrara M., Galli L., Comi L., Sterrantino G., Cenderello G., Zaccarelli M., Focà E., Roncadori A., Lazzarin A.; PRESTIGIO Study Group. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus // Antimicrob. Chemother. 2018. Vol. 73, No. 1. Р. 177–182. DOI: 10.1093/jac/dkx371.Gay C.L., Neo D.T., Devanathan A.S., Kuruc J.D., McGee K.S., Schmitz J.L., Sebastian J., Shaheen N.J., Ferrari G., McKellar M., Fiscus S.A., Hicks C.B., Robertson K., Kashuba A.D.M., Eron J.J., Margolis D.M. Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTIsparing antiretroviral therapy in acute HIV-infection // AIDS. 2020. Vol. 34, No. 13. Р. 1923–1931. DOI: 10.1097/QAD.0000000000002652.Gay C.L., Neo D.T., Devanathan A.S., Kuruc J.D., McGee K.S., Schmitz J.L., Sebastian J., Shaheen N.J., Ferrari G., McKellar M., Fiscus S.A., Hicks C.B., Robertson K., Kashuba A.D.M., Eron J.J., Margolis D.M. Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTIsparing antiretroviral therapy in acute HIV-infection // AIDS. 2020. Vol. 34, No. 13. Р. 1923–1931. DOI: 10.1097/QAD.0000000000002652.Song I., Borland J., Chen S., Guta P., Lou Y., Wilfret D., Wajima T., Savina P., Peppercorn A., Castellino S., Wagner D., Hosking L., Mosteller M., Rubio J.P., Piscitelli S.C. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir // Eur. J. Clin. Pharmacol. 2014. Vol. 70(10. Р. 1173–1179. DOI: 10.1007/s00228-014-1732-8.Song I., Borland J., Chen S., Guta P., Lou Y., Wilfret D., Wajima T., Savina P., Peppercorn A., Castellino S., Wagner D., Hosking L., Mosteller M., Rubio J.P., Piscitelli S.C. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir // Eur. J. Clin. Pharmacol. 2014. Vol. 70(10. Р. 1173–1179. DOI: 10.1007/s00228-014-1732-8.Zong J., Borland J., Jerva F., Wynne B., Choukour M., Song I. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects // Int. AIDS Soc. 2014. Vol. 17, No. 4, Suppl. 3. Р. 19584. DOI: 10.7448/IAS.17.4.19584.Zong J., Borland J., Jerva F., Wynne B., Choukour M., Song I. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects // Int. AIDS Soc. 2014. Vol. 17, No. 4, Suppl. 3. Р. 19584. DOI: 10.7448/IAS.17.4.19584.Усеинова А.Н., Егорова Е.А., Марьяненко С.П., Иванцова Н.Л. Наносистемы для доставки антиретровирусных лекарственных средств: возможности, проблемы и перспективы // ВИЧ-инфекция и иммуносупрессии. 2021. Т. 13, № 4. С. 64–76 DOI: 10.22328/2077-9828-2021-13-4-64-76.Useinova A.N., Egorova E.A., Mar’yanenko S.P., Kaliberdenko V.B., Koryanova K. N. Nanosystems for the delivery of antiretroviral drugs: opportunities, problems and prospects // HIV infection and immunosuppression, 2021, Vol. 13, No. 4, pр. 64–76 (In Russ.). DOI: 10.22328/2077-9828-2021-13-4-64-76.Chen A.Y., Adamek R.N., Dick B.L., Credille C.V., Morrison C.N., Cohen S.M. Targeting Metalloenzymes for Therapeutic Intervention // Chem. Rev. 2019. Vol. 119, No. 2. Р. 1323–1455. DOI: 10.1021/acs.chemrev.8b00201.Chen A.Y., Adamek R.N., Dick B.L., Credille C.V., Morrison C.N., Cohen S.M. Targeting Metalloenzymes for Therapeutic Intervention // Chem. Rev. 2019. Vol. 119, No. 2. Р. 1323–1455. DOI: 10.1021/acs.chemrev.8b00201.Patel P., Ford S.L., Crauwels H., Han K., Rossenu S., Neyens M., Griffith S., Hudson K.J., Margolis D., Baker M., Williams P., Spreen W. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies // Open Forum Infectious Diseases. 2019. Vol. 6, No. 2. Р. S865–S866. DOI: 10.1093/ofid/ofz360.2173.Patel P., Ford S.L., Crauwels H., Han K., Rossenu S., Neyens M., Griffith S., Hudson K.J., Margolis D., Baker M., Williams P., Spreen W. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies // Open Forum Infectious Diseases. 2019. Vol. 6, No. 2. Р. S865–S866. DOI: 10.1093/ofid/ofz360.2173.Patel P., Ford S.L., Lou Y., Bakshi K., Tenorio A.R., Zhang Z., Pan R., Spreen W. Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir // Clin. Pharmacol. Drug Dev. 2019. Vol. 8, No. 4. Р. 443–448. DOI: 10.1002/cpdd.620.Patel P., Ford S.L., Lou Y., Bakshi K., Tenorio A.R., Zhang Z., Pan R., Spreen W. Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir // Clin. Pharmacol. Drug Dev. 2019. Vol. 8, No. 4. Р. 443–448. DOI: 10.1002/cpdd.620.Kovač L., Časar Z. A literature review of the patent application publications on cabotegravir — an HIV integrase strand transfer inhibitor // Expert Opin Ther. Pat. 2020. Vol. 30, No. 3. Р. 195–208. DOI: 10.1080/13543776.2020.1717470.Kovač L., Časar Z. A literature review of the patent application publications on cabotegravir — an HIV integrase strand transfer inhibitor // Expert Opin Ther. Pat. 2020. Vol. 30, No. 3. Р. 195–208. DOI: 10.1080/13543776.2020.1717470.Pasternak A.O., Vroom J., Kootstra N.A., Wit F.W., de Bruin M., De Francesco D., Bakker M., Sabin C.A., Winston A., Prins J.M., Reiss P., Berkhout B. Co-morBidity in Relation to Aids (COBRA) Collaboration. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy // Elife. 2021. Vol. 10. e68174. DOI: 10.7554/eLife.68174.Pasternak A.O., Vroom J., Kootstra N.A., Wit F.W., de Bruin M., De Francesco D., Bakker M., Sabin C.A., Winston A., Prins J.M., Reiss P., Berkhout B. Co-morBidity in Relation to Aids (COBRA) Collaboration. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy // Elife. 2021. Vol. 10. e68174. DOI: 10.7554/eLife.68174.Clement M.E., Kofron R., Landovitz R.J. Long-acting injectable cabotegravir for the prevention of HIV infection // Curr. Opin HIV AIDS. 2020. Vol. 15, No. 1. Р. 19–26. DOI: 10.1097/COH.0000000000000597.Clement M.E., Kofron R., Landovitz R.J. Long-acting injectable cabotegravir for the prevention of HIV infection // Curr. Opin HIV AIDS. 2020. Vol. 15, No. 1. Р. 19–26. DOI: 10.1097/COH.0000000000000597.Schürmann D., Rudd D.J., Zhang S., De Lepeleire I., Robberechts M., Friedman E., Keicher Ch., Hüser A., Hofmann J., Grobler J.A., Stoch S.A., Iwamoto M., Matthews R.P. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial // The Lancet HIV. 2020. Vol. 7, No. 3. e164-e172. DOI: 10.1016/S2352-3018(19)30372-8.Schürmann D., Rudd D.J., Zhang S., De Lepeleire I., Robberechts M., Friedman E., Keicher Ch., Hüser A., Hofmann J., Grobler J.A., Stoch S.A., Iwamoto M., Matthews R.P. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial // The Lancet HIV. 2020. Vol. 7, No. 3. e164-e172. DOI: 10.1016/S2352-3018(19)30372-8.Cilento M.E., Reeve A.B., Michailidis E., Ilina T.V., Nagy E., Mitsuya H., Parniak M.A., Tedbury P.R., Sarafianos S.G. Development of Human Immunodeficiency Virus Type 1 Resistance to 4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains // Antimicrob Agents Chemother. 2021. Vol. 65, No. 12. e0116721. DOI: 10.1128/AAC.01167-21.Cilento M.E., Reeve A.B., Michailidis E., Ilina T.V., Nagy E., Mitsuya H., Parniak M.A., Tedbury P.R., Sarafianos S.G. Development of Human Immunodeficiency Virus Type 1 Resistance to 4’-Ethynyl-2-Fluoro-2’-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains // Antimicrob Agents Chemother. 2021. Vol. 65, No. 12. e0116721. DOI: 10.1128/AAC.01167-21.Barrett S.E., Teller R.S., Forster S.P., Li L., Mackey M.A., Skomski D., Yang Z., Fillgrove K.L., Doto G.J., Wood S.L., Lebron J., Grobler J.A., Sanchez R.I., Liu Z., Lu B., Niu T., Sun L., Gindy M.E. Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention // Antimicrob Agents Chemother. 2018 Sep 24. Vol. 62, No. 10. e01058–18. doi: 10.1128/AAC.01058–18. PMID: 30012772; PMCID: PMC6153840.Barrett S.E., Teller R.S., Forster S.P., Li L., Mackey M.A., Skomski D., Yang Z., Fillgrove K.L., Doto G.J., Wood S.L., Lebron J., Grobler J.A., Sanchez R.I., Liu Z., Lu B., Niu T., Sun L., Gindy M.E. Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention // Antimicrob Agents Chemother. 2018 Sep 24. Vol. 62, No. 10. e01058–18. doi: 10.1128/AAC.01058–18. PMID: 30012772; PMCID: PMC6153840.Markowitz M., Sarafianos S.G. EFdA (4 -ethynyl-2-fluoro-2 -deoxyadenosine, MK-8591): a novel HIV-1 reverse transcriptase translocation inhibitor // Curr. Opin HIV AIDS. 2018. Vol. 13, No. 4. Р. 294–299. DOI: 10.1097/COH.0000000000000467.Markowitz M., Sarafianos S.G. EFdA (4 -ethynyl-2-fluoro-2 -deoxyadenosine, MK-8591): a novel HIV-1 reverse transcriptase translocation inhibitor // Curr. Opin HIV AIDS. 2018. Vol. 13, No. 4. Р. 294–299. DOI: 10.1097/COH.0000000000000467.Christensen B.L., Tan D.H. An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV // Expert Opin Pharmacother. 2022. Vol. 23, No. 4. Р. 439–446. DOI: 10.1080/14656566.2022.2029409.Christensen B.L., Tan D.H. An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV // Expert Opin Pharmacother. 2022. Vol. 23, No. 4. Р. 439–446. DOI: 10.1080/14656566.2022.2029409.Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis Ph., Danner S. A., Mulder J., Loveday C., Christopherson C., Kwok Sh., Sninsky J., Boucher Ch.A.B. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC) // Infect. Dis. 1995. Vol. 171, No. 6. Р. 1411–1419. DOI: 10.1093/infdis/171.6.1411.Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis Ph., Danner S. A., Mulder J., Loveday C., Christopherson C., Kwok Sh., Sninsky J., Boucher Ch.A.B. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC) // Infect. Dis. 1995. Vol. 171, No. 6. Р. 1411–1419. DOI: 10.1093/infdis/171.6.1411.Bowman E.R., Cameron C., Richardson B., Kulkarni M., Gabriel J., Kettelhut A., Hornsby L., Kwiek J.J., Turner A.N., Malvestutto C., Bazan J., Koletar S.L., Doblecki-Lewis S., Lederman M.M., Cameron M., Klatt N.R., Lake J.E., Funderburg N.T. In Vitro Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles // Antimicrob. Agents Chemother. 2020. Vol. 65, No. 1. e01755–20. DOI: 10.1128/AAC.01755-20.Bowman E.R., Cameron C., Richardson B., Kulkarni M., Gabriel J., Kettelhut A., Hornsby L., Kwiek J.J., Turner A.N., Malvestutto C., Bazan J., Koletar S.L., Doblecki-Lewis S., Lederman M.M., Cameron M., Klatt N.R., Lake J.E., Funderburg N.T. In Vitro Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles // Antimicrob. Agents Chemother. 2020. Vol. 65, No. 1. e01755–20. DOI: 10.1128/AAC.01755-20.Bleasby K., Houle R., Hafey M., Lin M., Guo J., Lu B., Sanchez R.I., Fillgrove K.L. Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters // Viruses. 2021. Vol. 13. Р. 1566. DOI: 10.3390/v13081566.Bleasby K., Houle R., Hafey M., Lin M., Guo J., Lu B., Sanchez R.I., Fillgrove K.L. Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters // Viruses. 2021. Vol. 13. Р. 1566. DOI: 10.3390/v13081566.Hernandez M.M., Fahrny A., Jayaprakash A., Gers-Huber G., Dillon-White M., Audigé A., Mulder L.C.F., Sachidanandam R., Speck R.F., Simon V. Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice // Virol. 2020. Vol. 94, No. 5. e01543–19. DOI: 10.1128/JVI.01543-19.Hernandez M.M., Fahrny A., Jayaprakash A., Gers-Huber G., Dillon-White M., Audigé A., Mulder L.C.F., Sachidanandam R., Speck R.F., Simon V. Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice // Virol. 2020. Vol. 94, No. 5. e01543–19. DOI: 10.1128/JVI.01543-19.Jamburuthugoda V.K., Santos-Velazquez J.M., Skasko M., Operario D.J., Purohit V., Chugh P., Szymanski E.A., Wedekind J.E., Bambara R.A., Kim B. Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage // Biol. Chem. 2008. Vol. 283, No. 14. Р. 9206–9216. DOI: 10.1074/jbc.M710149200.Jamburuthugoda V.K., Santos-Velazquez J.M., Skasko M., Operario D.J., Purohit V., Chugh P., Szymanski E.A., Wedekind J.E., Bambara R.A., Kim B. Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage // Biol. Chem. 2008. Vol. 283, No. 14. Р. 9206–9216. DOI: 10.1074/jbc.M710149200.Tiraboschi J., Lattour N., Knobel H., Domingo P., Ribera E., Podzamczer D. Long-term efficacy and safety of nevirapine-containing regimens in viro-logically suppressed patients: a 17-year follow up // HIV Res. Clin. Pract. 2019. Vol. 20, No. 6. Р. 151–155. DOI: 10.1080/25787489.2020.1724760.Tiraboschi J., Lattour N., Knobel H., Domingo P., Ribera E., Podzamczer D. Long-term efficacy and safety of nevirapine-containing regimens in viro-logically suppressed patients: a 17-year follow up // HIV Res. Clin. Pract. 2019. Vol. 20, No. 6. Р. 151–155. DOI: 10.1080/25787489.2020.1724760.Paton N.I., Musaazi J., Kityo C., Walimbwa S., Hoppe A., Balyegisawa A., Kaimal A., Mirembe G., Tukamushabe P., Ategeka G., Hakim J., Mugerwa H., Siika A., Asienzo J., Castelnuovo B., Kiragga A., Kambugu A. NADIA Trial Team. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV // N. Engl. J. Med. 2021. Vol. 385, No. 4. Р. 330–341. DOI: 10.1056/NEJMoa2101609.Paton N.I., Musaazi J., Kityo C., Walimbwa S., Hoppe A., Balyegisawa A., Kaimal A., Mirembe G., Tukamushabe P., Ategeka G., Hakim J., Mugerwa H., Siika A., Asienzo J., Castelnuovo B., Kiragga A., Kambugu A. NADIA Trial Team. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV // N. Engl. J. Med. 2021. Vol. 385, No. 4. Р. 330–341. DOI: 10.1056/NEJMoa2101609.

The authors declare that there are no conflicts of interest present.